Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stress, Psychological 1Stomach Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Cervical Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Bites and Stings 1

Interventions

zanubrutinib 3Rituximab 3Bendamustine Hydrochloride 3ibrutinib 2talquetamab 1pirtobrutinib 1Sra protein, Drosophila 1Specimen Handling 1Sirolimus 1Prednisone 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Everolimus 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Waldenstrom Macroglobulinemia × Neoadjuvant Therapy × Clear all
NCT07259122 2025-12-02

ZBR in WM

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
43 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡